Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has earned an average recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage on the stock in the last […]